4D Molecular Therapeutics(US:FDMT) Globenewswire·2025-11-10 13:00Core Insights - 4D Molecular Therapeutics reported significant progress in Q3 2025, focusing on its lead product candidates 4D-150 and 4D-710, with a strong cash position extending operations into the second half of 2028 [2][5][9] Financial Performance - Cash, cash equivalents, and marketable securities totaled $372 million as of September 30, 2025, down from $505 million at the end of 2024, primarily due to operational cash usage [9][20] - Research and development expenses increased to $49.4 million in Q3 2025 from $38.5 million in Q3 2024, driven by Phase 3 trials for 4D-150 [10][18] - General and administrative expenses decreased to $11.8 million in Q3 2025 from $12.7 million in Q3 2024, attributed to reduced headcount [10][18] - The net loss for Q3 2025 was $56.9 million, compared to a net loss of $43.8 million in Q3 2024 [12][18] Strategic Partnerships and Investments - The company entered a strategic partnership with Otsuka Pharmaceutical, receiving an upfront payment of $85 million and expecting at least $50 million in cost-sharing over three years [5][6] - An equity investment of up to $11 million from the Cystic Fibrosis Foundation was announced to support the development of 4D-710 [5][11] Clinical Development Highlights - Positive long-term safety and efficacy data for 4D-150 in wet age-related macular degeneration (AMD) were reported from the Phase 1/2 PRISM trial, showing durable benefits over 1.5 to 2 years [5][11] - Enrollment for the 4FRONT Phase 3 trials in wet AMD is on track, with over 200 patients randomized and expected completion in Q1 2026 [11] - The 4D-710 program is advancing towards Phase 2, with interim safety and efficacy data expected by the end of 2025 [11] Leadership and Organizational Changes - The leadership team was strengthened with the promotion of Julie Clark, M.D., to Chief Medical Officer, and the addition of Liansheng Zhu, Ph.D., as SVP of Biometrics and Data Quality [6][11]